Skip to content

Janux Therapeutics JANX Cash Flow Statement

Q1 '26Q4 '25Q3 '25Q2 '25Q1 '25
-$24.36M-3.6%-$31.95M-58.0%-$24.31M+13.4%-$33.86M-468%-$23.51M-59.3%
$469K-9.6%$468K-8.6%$501K-1.8%$541K+6.9%$519K-2.4%
$9.27M-13.4%$9.52M+52.2%$9.04M-41.2%$10.96M+90.4%$10.7M+90.3%
-$12.34M+27.5%-$28.54M-70.7%-$12.86M-476%-$23.81M-138%-$17.02M-14.7%
$273K-26.4%$106K+152%$93K+272%$473K+398%$371K+88.3%
$8.29M+102%-$340.39M-199%
$3.55M+540%$2.94M-99.2%$493K-70.1%$954K-65.5%$554K-99.8%
-$506K+99.9%$0-100%-$4.06M-134%-$21.3M+89.3%-$356.86M-284%
-$12.61M+27.5%-$28.65M-70.9%-$12.95M-474%-$24.29M-140%-$17.4M-15.7%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

How much cash does Janux Therapeutics generate?
Janux Therapeutics (JANX) generated -$77.5M in operating cash flow over the trailing twelve months.
What is Janux Therapeutics's free cash flow?
After $945.0K of capital expenditures, Janux Therapeutics's free cash flow was -$78.5M over the trailing twelve months, down 68.7% year over year.
Where does Janux Therapeutics's cash flow data come from?
Every line is extracted from Janux Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.